Parsortix-based Blood Test Out-performs CA125 in Detecting Ovarian Cancer, Studies Show

Parsortix-based Blood Test Out-performs CA125 in Detecting Ovarian Cancer, Studies Show
Studies in the United States and Europe successfully demonstrate the potential of a Parsortix-based blood test to out-perform current tests in diagnosing ovarian cancer, Angle has recently announced. More specifically, the blood test demonstrates potential in discriminating between benign and malignant pelvic masses. Angle’s European study, ANG-001 (NCT02785731), is being led by Robert Zeillinger, PhD, at

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *